Table 1.

Summary of the current literature published regarding the use of recombinant activated factor VII in trauma

Ref. (year)	Patients (n)	Type of study	Type of patients	Dose (μg/kg)	Reported reduction in transfusion requirements	Mortality (deaths; n)	Thrombotic complications
[13] (1999)	1	Case report	Penetrating	60, 60	100%	0	None
[12] (2001)	7	Case series	Blunt and penetrating	120–212	100%	3	None
[14] (2002)	1	Case report	Penetrating	90	100%	1	None
[21] (2002)	19	Case series	Blunt and penetrating	129	78%	6	1 DVT
[22] (2002)	18	Case series	Blunt and penetrating	40	83%	5	1 IAT
[17] (2003)	5	Case series	Blunt and penetrating	80–144	60%	2	None
[19] (2003)	21	Case series	Multi-trauma and surgical	30–180	86%	5	None
[20] (2004)	29	Retrospective matched case series	Blunt and penetrating	40	100%	11	None
[32] (2004)	24	Retrospective chart review	Blunt and penetrating	?	100%	9	None
[18] (2004)	81	Retrospective cohort	Blunt and penetrating	48–148	80%	47	None
Unpublished (2004)	277	Prospective phase II	Blunt and penetrating	200, 100, 100	Decreased	69	None

DVT, deep vein thrombosis; IAT, iliac artery thrombosis.